The FDA approved cemiplimab-rwlc (Libtayo) for treatment of locally advanced, or metastatic, cutaneous squamous cell carcinoma (CSCC). This is the first drug treatment approved for advanced CSCC, the second most common cancer in the U.S. Please see the FDA website for more information.
Recent Posts
- The Art of Compassionate Care in Nursing
- Impact of Wearable Technology on Patient Monitoring in The Medical Field
- Navigating the Complexities of Pediatric Emergency Medicine
- Empowering EMS with PEPID’s EMS Suite: A Leap Towards Safer and More Efficient Patient Care
- The Doctor is In: A Guide to Clinical Decision Support Apps